ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage biopharmaceutical company that reached public markets through a business combination with ITHAX Acquisition Corp., a special purpose acquisition company sponsored by Ithax Holding LLC that completed its IPO in 2021. The company is focused on developing therapies for rare kidney diseases and neuroinflammation, with its pipeline anchored by the Cholesterol Efflux Mediator platform and IC 100, an anti-ASC inflammasome therapy candidate. This 10-Q, filed with the SEC on May 13, 2022, reflects the company's reporting obligations during the pre-merger period. The business combination closed in December 2022, with the combined entity listed on Nasdaq under the ZVSA ticker. Sign up on SpacDesk for the full filing history, deal timeline, and pipeline data on ZVSA.